- Record: found
- Abstract: not found
- Article: not found
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
P.D. Miller ,
G. Hattersley ,
E. Lau ,
L.A. Fitzpatrick ,
A.G. Harris ,
G.C. Williams ,
M.-Y. Hu ,
B.J. Riis ,
L. Russo ,
C. Christiansen
March 2019
March 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Abaloparatide is a 34-amino acid peptide that selectively binds to the RG conformation
of the parathyroid hormone receptor type 1. It was developed for the treatment of
women with postmenopausal osteoporosis at high risk of fracture. In ACTIVE, an 18-month
phase 3 study (NCT01343004), abaloparatide increased bone mineral density (BMD), decreased
the risk of vertebral and nonvertebral fractures compared with placebo, and decreased
the risk of major osteoporotic fractures compared with placebo and teriparatide. Here,
we report a prospective, exploratory BMD responder analysis from ACTIVE.